Education
About Us
Working with TipRanks
Follow Us
Entero Therapeutics, Inc. (ENTO)
:ENTO
RESEARCH TOOLSreports
ENTO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.19 - $4.58
Previous Close$0.65
Volume60.40K
Average Volume (3M)393.28K
Market Cap
$2.28M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.73
Shares Outstanding4,754,030
10 Day Avg. Volume65,696
30 Day Avg. Volume393,283
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Entero Therapeutics News
PremiumCompany Announcements
Entero Therapeutics Appoints Richard Paolone as Interim CEO
PremiumCompany Announcements
Entero Therapeutics Announces Board of Directors Restructuring
PremiumCompany Announcements
Entero Therapeutics Strikes Deal for Drug Trial Compliance Tech---
Ownership Overview
1.97% Insiders
0.51% Mutual Funds
0.55% Other Institutional Investors
96.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ENTO FAQ
What was Entero Therapeutics, Inc.’s price range in the past 12 months?
Entero Therapeutics, Inc. lowest stock price was $0.18 and its highest was $4.58 in the past 12 months.
What is Entero Therapeutics, Inc.’s market cap?
Entero Therapeutics, Inc.’s market cap is $2.28M.
When is Entero Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Entero Therapeutics, Inc.’s earnings last quarter?
Entero Therapeutics, Inc. released its earnings results on Aug 13, 2019. The company reported -$525 earnings per share for the quarter, missing the consensus estimate of N/A by -$525.
Is Entero Therapeutics, Inc. overvalued?
According to Wall Street analysts Entero Therapeutics, Inc.’s price is currently Overvalued.
Does Entero Therapeutics, Inc. pay dividends?
Entero Therapeutics, Inc. does not currently pay dividends.
What is Entero Therapeutics, Inc.’s EPS estimate?
Entero Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entero Therapeutics, Inc. have?
Entero Therapeutics, Inc. has 4,754,030 shares outstanding.
What happened to Entero Therapeutics, Inc.’s price movement after its last earnings report?
Entero Therapeutics, Inc. reported an EPS of -$525 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Entero Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ENTO
---
Company Description
Entero Therapeutics, Inc.
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
---
ENTO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering ENTO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-68.55%
assigned a buy rating 10 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -68.55% per trade.
---